Arc Institute
@arcinstitute.org
A new scientific institution for curiosity-driven biomedical science and technology.
Work published today in @natbiotech.nature.com from Arc’s Luke Gilbert and Patrick Hsu labs presents a new way to insert large DNA sequences into the genome using engineered recombinases that don’t require DNA cutting or rely on the cell's repair machinery.
November 6, 2025 at 5:46 PM
Work published today in @natbiotech.nature.com from Arc’s Luke Gilbert and Patrick Hsu labs presents a new way to insert large DNA sequences into the genome using engineered recombinases that don’t require DNA cutting or rely on the cell's repair machinery.
A study out today in @natgenet.nature.com from Core Investigator Luke Gilbert, Haolong Li, & others identifies PTGES3 as a critical regulator of androgen receptor (AR) protein levels in prostate cancer, revealing a potential new target for tumors that become treatment-resistant.
November 5, 2025 at 4:21 PM
A study out today in @natgenet.nature.com from Core Investigator Luke Gilbert, Haolong Li, & others identifies PTGES3 as a critical regulator of androgen receptor (AR) protein levels in prostate cancer, revealing a potential new target for tumors that become treatment-resistant.
Welcome to our 9th Core Investigator and first physician-scientist, John Pluvinage. His team investigates the hidden overlap between autoimmunity and neurodegeneration, developing targeted treatments for mysterious neurological cases and common dementias.
October 29, 2025 at 3:25 PM
Welcome to our 9th Core Investigator and first physician-scientist, John Pluvinage. His team investigates the hidden overlap between autoimmunity and neurodegeneration, developing targeted treatments for mysterious neurological cases and common dementias.
The genetic code is full of synonymous codons that, for decades, were assumed to be interchangeable.
Today, with NVIDIA, co-led by @genophoria.bsky.social, we announce CodonFM, a family of open-source AI models that reveal the grammar underlying codon choice: developer.nvidia.com/blog/introdu...
Today, with NVIDIA, co-led by @genophoria.bsky.social, we announce CodonFM, a family of open-source AI models that reveal the grammar underlying codon choice: developer.nvidia.com/blog/introdu...
Introducing the CodonFM Open Model for RNA Design and Analysis | NVIDIA Technical Blog
Open research is critical for driving innovation, and many breakthroughs in AI and science are achieved through open collaboration. In the field of digital biology research, NVIDIA Clara supports this...
developer.nvidia.com
October 28, 2025 at 8:55 PM
The genetic code is full of synonymous codons that, for decades, were assumed to be interchangeable.
Today, with NVIDIA, co-led by @genophoria.bsky.social, we announce CodonFM, a family of open-source AI models that reveal the grammar underlying codon choice: developer.nvidia.com/blog/introdu...
Today, with NVIDIA, co-led by @genophoria.bsky.social, we announce CodonFM, a family of open-source AI models that reveal the grammar underlying codon choice: developer.nvidia.com/blog/introdu...
Arc Core Investigator @genophoria.bsky.social will speak on a free, online panel with @tkaraletsos.bsky.social, @emmalundberg.bsky.social, and @ronalfa.bsky.social on Wed., Oct. 29, as part of GENbio's “The State of AI in Drug Discovery in 2025.” Register at: webinars.liebertpub.com/e/the-state-...
October 24, 2025 at 5:32 PM
Arc Core Investigator @genophoria.bsky.social will speak on a free, online panel with @tkaraletsos.bsky.social, @emmalundberg.bsky.social, and @ronalfa.bsky.social on Wed., Oct. 29, as part of GENbio's “The State of AI in Drug Discovery in 2025.” Register at: webinars.liebertpub.com/e/the-state-...
Published today in @natureportfolio.nature.com Biotechnology, Laine Goudy, Luke Gilbert, Alex Marson, & colleagues report an epigenetic editing platform that safely reprograms multiple genes in human T cells without many of the challenges & risks associated with traditional gene editing approaches.
October 21, 2025 at 4:43 PM
Published today in @natureportfolio.nature.com Biotechnology, Laine Goudy, Luke Gilbert, Alex Marson, & colleagues report an epigenetic editing platform that safely reprograms multiple genes in human T cells without many of the challenges & risks associated with traditional gene editing approaches.
Arc is looking for an outstanding early-career scientist to be our next Science Fellow. This program provides resources and freedom for those looking to transition into a principal investigator role immediately after doctoral training. Apply here: arcinstitute.org/programs/sea...
October 13, 2025 at 7:36 PM
Arc is looking for an outstanding early-career scientist to be our next Science Fellow. This program provides resources and freedom for those looking to transition into a principal investigator role immediately after doctoral training. Apply here: arcinstitute.org/programs/sea...
Hear how Arc, Ultima Genomics, and @10xgenomics.bsky.social are partnering to generate perturbation data at the scale needed to train virtual cell models on The Bio Report podcast with guests @genophoria.bsky.social, Gilad Almogy, and
Serge Saxonov: thebioreport.podbean.com/e/transformi...
Serge Saxonov: thebioreport.podbean.com/e/transformi...
October 9, 2025 at 4:51 PM
Hear how Arc, Ultima Genomics, and @10xgenomics.bsky.social are partnering to generate perturbation data at the scale needed to train virtual cell models on The Bio Report podcast with guests @genophoria.bsky.social, Gilad Almogy, and
Serge Saxonov: thebioreport.podbean.com/e/transformi...
Serge Saxonov: thebioreport.podbean.com/e/transformi...
Arc's community continues to grow this fall with our 9th Core Investigator John Pluvinage and 3rd Science Fellow @mayaarce.bsky.social joining us in Palo Alto, along with 7 Innovation Investigators and 15 Ignite Awardees at our partner universities.
Learn more:
arcinstitute.org/news/faculty...
Learn more:
arcinstitute.org/news/faculty...
Arc Institute Adds Two New Labs; Announces 2025 Cohort of Innovation Investigators and Ignite Awardees | Arc Institute
We are excited to launch three parallel searches for our curiosity-driven Laboratories.
arcinstitute.org
October 7, 2025 at 7:29 PM
Arc's community continues to grow this fall with our 9th Core Investigator John Pluvinage and 3rd Science Fellow @mayaarce.bsky.social joining us in Palo Alto, along with 7 Innovation Investigators and 15 Ignite Awardees at our partner universities.
Learn more:
arcinstitute.org/news/faculty...
Learn more:
arcinstitute.org/news/faculty...
For decades, human genome editing has been limited to small, localized modifications.
Today, in a new paper published in @science.org , researchers from Arc's Hsu lab show that bridge recombinase technology is capable of large-scale genomic rearrangements in human cells.
Today, in a new paper published in @science.org , researchers from Arc's Hsu lab show that bridge recombinase technology is capable of large-scale genomic rearrangements in human cells.
September 25, 2025 at 6:27 PM
For decades, human genome editing has been limited to small, localized modifications.
Today, in a new paper published in @science.org , researchers from Arc's Hsu lab show that bridge recombinase technology is capable of large-scale genomic rearrangements in human cells.
Today, in a new paper published in @science.org , researchers from Arc's Hsu lab show that bridge recombinase technology is capable of large-scale genomic rearrangements in human cells.
New work from Arc's @pauldatlinger.bsky.social of our Genome Engineering Technology Center. Congrats!
CAR T cells showcase the enormous potential of cell therapies, but often fail due to lack of evolutionary optimization. Today in @nature.com , we use #CELLFIE to engineer cell therapies at scale and share the largest resource of CRISPR screens in CAR T cells. www.nature.com/articles/s41...
Systematic discovery of CRISPR-boosted CAR T cell immunotherapies - Nature
CELLFIE, a CRISPR platform for optimizing cell-based immunotherapies, identifies gene knockouts that enhance CAR T cell efficacy using in vitro and in vivo screens.
www.nature.com
September 24, 2025 at 11:53 PM
New work from Arc's @pauldatlinger.bsky.social of our Genome Engineering Technology Center. Congrats!
Reposted by Arc Institute
Having often dealt with the frustration of binder-limited projects, we sought a more accessible source for nanobodies than yeast display or llama. Here we introduce Germinal, computationally designing antibody-like binders with such a hit rate that only tens need to be screened for each target.
September 24, 2025 at 4:32 PM
Having often dealt with the frustration of binder-limited projects, we sought a more accessible source for nanobodies than yeast display or llama. Here we introduce Germinal, computationally designing antibody-like binders with such a hit rate that only tens need to be screened for each target.
In another preprint from the @brianhie.bsky.social Lab and @synbiogaolab.bsky.social, they introduce Germinal, a generative AI system for de novo antibody design.
Germinal produces functional nanobodies in just dozens of tests, making custom antibody design more accessible than ever before.
Germinal produces functional nanobodies in just dozens of tests, making custom antibody design more accessible than ever before.
September 24, 2025 at 3:07 PM
In another preprint from the @brianhie.bsky.social Lab and @synbiogaolab.bsky.social, they introduce Germinal, a generative AI system for de novo antibody design.
Germinal produces functional nanobodies in just dozens of tests, making custom antibody design more accessible than ever before.
Germinal produces functional nanobodies in just dozens of tests, making custom antibody design more accessible than ever before.
Arc Innovation Investigator research highlight:
Stanford Professor Zhenan Bao and colleagues have developed NeuroString, a hair-thin multichannel biosensor and stimulator with promising potential applications in drug delivery, nerve stimulation, smart fabrics, and more.
Stanford Professor Zhenan Bao and colleagues have developed NeuroString, a hair-thin multichannel biosensor and stimulator with promising potential applications in drug delivery, nerve stimulation, smart fabrics, and more.
September 18, 2025 at 5:14 PM
Arc Innovation Investigator research highlight:
Stanford Professor Zhenan Bao and colleagues have developed NeuroString, a hair-thin multichannel biosensor and stimulator with promising potential applications in drug delivery, nerve stimulation, smart fabrics, and more.
Stanford Professor Zhenan Bao and colleagues have developed NeuroString, a hair-thin multichannel biosensor and stimulator with promising potential applications in drug delivery, nerve stimulation, smart fabrics, and more.
Reposted by Arc Institute
Genome foundation models, Evo 1 and Evo 2, have now generated viable bacteriophage genomes, demonstrating experimental validation of whole genomes designed by AI!
@arcinstitute.org @brianhie.bsky.social @samuelhking.bsky.social
Read more at GEN:
www.genengnews.com/topics/artif...
@arcinstitute.org @brianhie.bsky.social @samuelhking.bsky.social
Read more at GEN:
www.genengnews.com/topics/artif...
AI Designs Viable Bacteriophage Genomes, Combats Antibiotic Resistance
AI-guided design of 16 functional bacteriophage genomes offers a path for phage-based therapies against antibiotic-resistant infections.
www.genengnews.com
September 17, 2025 at 3:21 PM
Genome foundation models, Evo 1 and Evo 2, have now generated viable bacteriophage genomes, demonstrating experimental validation of whole genomes designed by AI!
@arcinstitute.org @brianhie.bsky.social @samuelhking.bsky.social
Read more at GEN:
www.genengnews.com/topics/artif...
@arcinstitute.org @brianhie.bsky.social @samuelhking.bsky.social
Read more at GEN:
www.genengnews.com/topics/artif...
In a new preprint from @brianhie.bsky.social's lab, the team reports the first generative design of viable bacteriophage genomes.
Leveraging Evo 1 & Evo 2, they generated whole genome sequences, resulting in 16 viable phages with distinct genomic architectures.
Leveraging Evo 1 & Evo 2, they generated whole genome sequences, resulting in 16 viable phages with distinct genomic architectures.
September 17, 2025 at 3:12 PM
In a new preprint from @brianhie.bsky.social's lab, the team reports the first generative design of viable bacteriophage genomes.
Leveraging Evo 1 & Evo 2, they generated whole genome sequences, resulting in 16 viable phages with distinct genomic architectures.
Leveraging Evo 1 & Evo 2, they generated whole genome sequences, resulting in 16 viable phages with distinct genomic architectures.
Reposted by Arc Institute
🧠 Arc Workshop at the upcoming scverse conference 2025 🧠
Processing and Modeling Large-Scale Single-Cell Perturbation Data with Machine Learning
🧵
@arcinstitute.org
#scverse2025 #PerturbSeq #MachineLearning #SingleCell #CRISPR #GenomicScreening #VirtualCells
Processing and Modeling Large-Scale Single-Cell Perturbation Data with Machine Learning
🧵
@arcinstitute.org
#scverse2025 #PerturbSeq #MachineLearning #SingleCell #CRISPR #GenomicScreening #VirtualCells
September 9, 2025 at 4:27 PM
🧠 Arc Workshop at the upcoming scverse conference 2025 🧠
Processing and Modeling Large-Scale Single-Cell Perturbation Data with Machine Learning
🧵
@arcinstitute.org
#scverse2025 #PerturbSeq #MachineLearning #SingleCell #CRISPR #GenomicScreening #VirtualCells
Processing and Modeling Large-Scale Single-Cell Perturbation Data with Machine Learning
🧵
@arcinstitute.org
#scverse2025 #PerturbSeq #MachineLearning #SingleCell #CRISPR #GenomicScreening #VirtualCells
Welcome to our third Science Fellow, Maya Arce (@mayaarce.bsky.social). Her team uses large-scale genomic screening and CRISPR editing to decode how genetic regulators control immune cell behavior.
September 3, 2025 at 4:12 PM
Welcome to our third Science Fellow, Maya Arce (@mayaarce.bsky.social). Her team uses large-scale genomic screening and CRISPR editing to decode how genetic regulators control immune cell behavior.
In this blog post from Arc scientists, learn about some of the decisions that went into the dataset and three-metric evaluation framework developed for the first Virtual Cell Challenge.
arcinstitute.org/news/behind-...
arcinstitute.org/news/behind-...
Behind the Data of the Virtual Cell Challenge | Arc Institute
To enable meaningful model comparison in the Virtual Cell Challenge, we needed more than just a new Perturb-seq dataset; we needed a high-quality and high-fidelity benchmark. This required us to make ...
arcinstitute.org
August 22, 2025 at 7:17 PM
In this blog post from Arc scientists, learn about some of the decisions that went into the dataset and three-metric evaluation framework developed for the first Virtual Cell Challenge.
arcinstitute.org/news/behind-...
arcinstitute.org/news/behind-...
Over 2,500 people have registered for the Virtual Cell Challenge and we're nearly three months away from when final submissions are due. We created a notebook tutorial showing how to train Arc's STATE model for context generalization for anyone looking to get started: www.youtube.com/watch?v=1kKH...
How to Train Arc's STATE Model for the Virtual Cell Challenge
YouTube video by Arc Institute
www.youtube.com
August 13, 2025 at 6:47 PM
Over 2,500 people have registered for the Virtual Cell Challenge and we're nearly three months away from when final submissions are due. We created a notebook tutorial showing how to train Arc's STATE model for context generalization for anyone looking to get started: www.youtube.com/watch?v=1kKH...
Reposted by Arc Institute
Our latest Forum podcast is a roundtable on foundation models, featuring guests Marie Lopez, @instadeep.bsky.social head of genomics AI and @brianhie.bsky.social of @stanford.edu and @arcinstitute.org shows.acast.com/forum/episod...
Foundation Models Roundtable: Lopez and Hie | Forum
shows.acast.com
July 29, 2025 at 2:52 PM
Our latest Forum podcast is a roundtable on foundation models, featuring guests Marie Lopez, @instadeep.bsky.social head of genomics AI and @brianhie.bsky.social of @stanford.edu and @arcinstitute.org shows.acast.com/forum/episod...
Over 2,000 people have registered for the Virtual Cell Challenge to create an AI model that can generalize for unseen perturbations. Hundreds of competitors have been submitting results from their models and the race, as you can see from the leaderboard, is heating up:
July 25, 2025 at 9:32 PM
Over 2,000 people have registered for the Virtual Cell Challenge to create an AI model that can generalize for unseen perturbations. Hundreds of competitors have been submitting results from their models and the race, as you can see from the leaderboard, is heating up:
Our 2nd Investigator Retreat wrapped up with talks from Core Investigators Christoph Thaiss and Felix Horns, our incoming Science Fellow Maya Arce, and some of our Innovation Investigators and Ignite Awardees. We look forward to seeing how the connections made this week turn into new collaborations.
July 19, 2025 at 2:46 AM
Our 2nd Investigator Retreat wrapped up with talks from Core Investigators Christoph Thaiss and Felix Horns, our incoming Science Fellow Maya Arce, and some of our Innovation Investigators and Ignite Awardees. We look forward to seeing how the connections made this week turn into new collaborations.
The Arc Institute Investigator Retreat is off to a great start! Huge thanks to Dave Burke and @brianhie.bsky.social for for sharing their computational research, and to Isha Jain, Will Allen, Faranak Fattahi, and Alex Pollen for diving into cell biology and neuroscience.
July 17, 2025 at 4:15 PM
The Arc Institute Investigator Retreat is off to a great start! Huge thanks to Dave Burke and @brianhie.bsky.social for for sharing their computational research, and to Isha Jain, Will Allen, Faranak Fattahi, and Alex Pollen for diving into cell biology and neuroscience.
Core Investigator @lingyinli.bsky.social's new paper in Nature Chemical Biology investigates why human STING inhibitors have shown limited efficacy, despite strong activity in mouse models.
July 3, 2025 at 4:31 PM
Core Investigator @lingyinli.bsky.social's new paper in Nature Chemical Biology investigates why human STING inhibitors have shown limited efficacy, despite strong activity in mouse models.